

// 3 NOVEMBER 2020

## **eTheRNA extends mRNA contract manufacturing services**

*High throughput research grade material to GMP production batches.*

### **Niel (Belgium)**

In response to growing international demand, eTheRNA today announced the extension of its mRNA production services to include high throughput research grade mRNA in addition to its GMP capabilities. From its facilities on the Antwerp University Science Park in Niel, the company can develop processes and manufacture mRNA in amounts ranging from research and pre-clinical batches to full GMP production lots for clinical trial supplies. In providing these services, eTheRNA leverages extensive experience gained in developing its own pipeline of mRNA immunotherapies for the treatment of cancer and infectious disease.

Dr Bernard Sagaert, VP Manufacturing, eTheRNA commented: “We have extended our contract manufacturing services in response to a growing number of requests from third parties from around the world. With our two purpose-built mRNA-units, we have the optimal infrastructure to support mRNA-based projects from initial plasmid DNA development and optimization, through linearization, in-vitro translation, mRNA purification and quality control to industrialized GMP production. We can support customers ranging from small academic groups with whom we can partner through to established companies looking for GMP manufacturing capacity.”

The full range of services offered by eTheRNA includes:

Plasmid DNA – design and production of plasmid DNA tailored to customer requirements

Research Grade RNA – mRNA, Guide RNA, Long RNA and dsRNA can be supplied from 100 µg to gram scale and can include multiple constructs for screening purposes.

GMP Grade RNA – mRNA, Long RNA and Guide RNA drug substances can be manufactured by in-vitro transcription in quantities from 100 mg to gram scale. Various upstream and downstream purification processes are available including different capping and adenylation techniques and purpose-based purification techniques which include precipitation, column chromatography, double stranded RNA reduction, tangential flow filtration, bioburden reduction and sterile filtration. Multiple APIs can be formulated into a drug product and sterile fill & finish is available. GMP batch release is in full accordance with cGMP.

Also, by drawing on its own experience with clinical trials, eTheRNA can provide support to customers in CMC file writing.

### About eTheRNA Immunotherapies NV

eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its multiple RNA, formulation and manufacturing technology platforms. The company is headquartered in Belgium and was established in 2013 and its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company’s ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding. Further details relating to eTheRNA’s R&D pipeline can be found at <https://www.etherna.be/immunotherapies-rd-pipeline/>.